Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
Mary Maille Lyons
Overview
Structured Data
Issues
Contributors
Activity
All edits
Edits on 14 Dec, 2021
"Remove inverse infobox"
Golden AI
edited on 14 Dec, 2021
Edits made to:
Infobox
(
-3
properties)
Infobox
Patent primary examiner of
US Patent 11175291 Signatures and determinants for diagnosing infections and methods of use thereof
US Patent 11179453 Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
US Patent 11179462 Molecular adjuvant and vaccine
Edits on 25 Nov, 2021
Golden AI
edited on 25 Nov, 2021
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent primary examiner of
US Patent 11179462 Molecular adjuvant and vaccine
Golden AI
edited on 25 Nov, 2021
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent primary examiner of
US Patent 11179453 Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
Edits on 19 Nov, 2021
Golden AI
edited on 19 Nov, 2021
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent primary examiner of
US Patent 11175291 Signatures and determinants for diagnosing infections and methods of use thereof
"Created via: Entity Importer"
Golden AI
created this topic on 19 Nov, 2021
Edits made to:
Infobox
(
+2
properties)
Mary Maille Lyons
Infobox
Is a
Person
Current Employer
United States Patent and Trademark Office
Find more people like Mary Maille Lyons
Use the Golden Query Tool to discover related individuals, professionals, or experts with similar interests, expertise, or connections in the Knowledge Graph.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE